Hepatitis B Virus (HBV)

Atorvastatin calcium: EFFICACY(10)

Atorvastatin was also effective in some patients with homozygous FH. In a pilot study involving eight patients with homozygous FH, the mean decrease in LDL-C with atorvasta-tin 80mg/day was 30% for patients not on plasmapheresis and 31% for patients who continued plasmapheresis . In an open-label, uncontrolled study in 41 patients with homozygous FH or with severe hypercholesterolemia who had less than 15% prior LDL-C reduction with maximum doses of combination therapy (HMG-CoA reductase inhibitor, resin and plasmapheresis), atorvastatin 40 to 80mg/day lowered LDL-C by 11% to 55% . Mean LDL-C reduction was 19% in two patients with absent receptor function. Six patients had a less than 10% response totreatment. ventolin inhaler


A large proportion (45%) of the patients in the clinical trials of atorvastatin werewomen. Subset analysis of pooled data from the clinical trials showed that atorvastatin provided a consistent dose-related reduction in LDL-C level in both men andwomenacross the recommended dose range (Table 4) . Results from the clinical trials described above also demonstrate consistency between men andwomenin modifications of other lipoprotein fractions (total cholesterol, triglycerides, VLDL-C, apo B, HDL-C, etc).

TABLE 4 Efficacy of low density lipoprotein cholesterol lowering in men and women: Subset analysis from pooled studies (mild to moderate hypercholesterolemia)

Atorvastatin dose % CMen (n=1109) hangeWomen (n=915)
10 mg/day -34% -38%
20 mg/day -43% -44%
40 mg/day -47% -47%
80 mg/day -52% -54%

Based on data from reference 70

Category: Calcium

Tags: Atorvastatin, Coronary artery disease, Dyslipidemia, HMG-CoA reductase inhibitors, Hypercholesterolemia, Statins

Leave a Reply

Your email address will not be published. Required fields are marked *